Get started
Author

Baptiste Archambaud

Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial
2022 · Patricia Pautier, Antoine Italiano, et al. · The Lancet Oncology · 134
PDF
Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma
2024 · Patricia Pautier, Antoine Italiano, et al. · New England Journal of Medicine · 88
PDF
Escherichia coli –Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer
2022 · Anne-Gaëlle Goubet, Leonardo Lordello, et al. · Cancer Discovery · 81
AcSé-ESMART, a European precision cancer medicine proof-of-concept platform trial
2023 · Birgit Geoerger, Xavier Paoletti, et al. · Nature Medicine · 17
PDF
Precision cancer medicine platform trials: Concepts and design of AcSé-ESMART
2024 · Birgit Geoerger, Francisco Bautista, et al. · European Journal of Cancer · 11
Bacteria-specific CXCL13-producing follicular helper T cells are putative prognostic markers to neoadjuvant PD-1 blockade in muscle-invasive urothelial carcinoma.
2022 · Anne-Gaëlle Goubet, Carolina Alves Costa Silva, et al. · Journal of Clinical Oncology · 10
1913O A randomised, multicenter phase-III study comparing doxorubicin (dox) alone versus dox with trabectedin (trab) followed by trab in non-progressive patients (pts) as first-line therapy, in pts with metastatic or unresectable leiomyosarcoma (LMS): Final results of the LMS-04 study
2023 · P. Pautier, A. Italiano, et al. · Annals of Oncology · 7
PDF
Abstract CT019: Phase I/II study of the PARP inhibitor olaparib and ATR inhibitor ceralasertib in children with advanced malignancies: Arm N of the AcSé-ESMART trial
2023 · Susanne A. Gatz, Alba Rubio San Simón, et al. · Cancer Research · 7
Abstract CT088: Phase I/II study of the PARP inhibitor olaparib in combination with irinotecan in children with advanced malignancies: arm D of the AcSé-ESMART trial
2023 · Susanne A. Gatz, Pablo Berlanga, et al. · Cancer Research · 6
855MO Adjuvant immunotherapy after salvage surgery in head and neck cancer squamous cell carcinoma (HNSCC): Phase II trial evaluating the efficacy and the toxicity of Nivolumab (ADJORL1)
2023 · J. Guerlain, N. Cozic, et al. · Annals of Oncology · 5
PDF
International real-world study of combination immunotherapy sequences in metastatic melanoma
2025 · Mora Guardamagna, Sarah E Lochrin, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
Étude internationale en vie réelle sur les séquences d’immunothérapie combinée dans le mélanome métastatique
2025 · M. Guardamagna, S.E. Lochrin, et al. · Annales de Dermatologie et de Vénéréologie - FMC
Isoenzymes de la LDH et pronostic du mélanome : nouvelle approche pour les stades IV
2025 · L. Soumoy, V. Quidville, et al. · Annales de Dermatologie et de Vénéréologie - FMC
Doxorubicin-Trabectedin With Trabectedin Maintenance in Leiomyosarcoma
2025 · Patricia Pautier, Antoine Italiano, et al. · Obstetrical & Gynecological Survey
3MO LDH isoforms shape the immune microenvironment and impact treatment response and survival in metastatic melanoma
2024 · L. Soumoy, V. Quidville, et al. · Immuno-Oncology Technology
PDF
1106P NivoLag-when: International real-world study of combination immunotherapy sequences in melanoma
2024 · M. Guardamagna, C. Gaudy Marqueste, et al. · Annals of Oncology
PDF
909P Immunoscore-IC predicts nivolumab efficacy as adjuvant treatment after salvage surgery in head and neck cancer squamous cell carcinoma: The ADJORL1 trial
2024 · A. Marhic, J. Guerlain, et al. · Annals of Oncology
PDF
Survie à long terme sans progression de patients atteints d’un mélanome de stade IV traités par immunothérapie néoadjuvante suivie de procédures locales pour contrôler la maladie résiduelle
2023 · D. Belkadi-Sadou, A. Marchand, et al. · Annales de Dermatologie et de Vénéréologie - FMC
Suivi au long terme des répondeurs complets aux inhibiteurs de point de contrôle immunitaire (ICI) ou à la thérapie ciblée (TC) dans le mélanome avancé
2023 · C. Boutros, D. Belkadi-Sadou, et al. · Annales de Dermatologie et de Vénéréologie - FMC
1116P Long term outcome of complete responders to immune checkpoint inhibitors (ICI) or target therapy (TT) in advanced melanoma
2023 · C. Boutros, D. Belkadi-Sadou, et al. · Annals of Oncology
PDF
1097P Durable relapse-free survival in stage IV melanoma patients (pts) treated with neoadjuvant immune-checkpoint inhibitor (ICI) followed by local procedures
2023 · D. Belkadi-Sadou, A. Marchand, et al. · Annals of Oncology
PDF
Data from Escherichia coli–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer
2023 · Anne-Gaëlle Goubet, Leonardo Lordello, et al.
Data from Escherichia coli–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer
2023 · Anne-Gaëlle Goubet, Leonardo Lordello, et al.
Supplementary Figure from Escherichia coli–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer
2023 · Anne-Gaëlle Goubet, Leonardo Lordello, et al.
Supplementary Figure from Escherichia coli–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer
2023 · Anne-Gaëlle Goubet, Leonardo Lordello, et al.
Works count: 26
Citation count: 369
H-index: 7
I10-index: 6
Year
Topic
Type